|
1
|
Wu MY and Hu YM: LeukemiaZhu futang
practice of pediatrics. Hu YM and Jiang ZF: People's medical
publishing house Co., Ltd.; Beijing: pp. 2351. 2015
|
|
2
|
Pui CH, Robison LL and Look AT: Acute
lymphoblastic leukaemia. Lancet. 371:1030–1043. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pui CH, Carroll WL, Meshinchi S and Arceci
RJ: Biology, risk stratification, and therapy of pediatric acute
leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garcia-Manero G, Yang H, Kuang SQ, O'Brien
S, Thomas D and Kantarjian H: Epigenetics of acute lymphocytic
leukemia. Semin Hematol. 46:24–32. 2009. View Article : Google Scholar
|
|
5
|
Issa JP, Baylin SB and Herman JG: DNA
methylation changes in hematologic malignancies: Biologic and
clinical implications. Leukemia. 11 (Suppl 1):S7–S11. 1997.
|
|
6
|
Kuang SQ, Tong WG, Yang H, Lin W, Lee MK,
Fang ZH, Wei Y, Jelinek J, Issa JP and Garcia-Manero G: Genome-wide
identification of aberrantly methylated promoter associated CpG
islands in acute lymphocytic leukemia. Leukemia. 22:1529–1538.
2008. View Article : Google Scholar
|
|
7
|
Roman-Gomez J, Jimenez-Velasco A,
Castillejo JA, Agirre X, Barrios M, Navarro G, Molina FJ, Calasanz
MJ, Prosper F, Heiniger A and Torres A: Promoter hypermethylation
of cancer-related genes: A strong independent prognostic factor in
acute lymphoblastic leukemia. Blood. 104:2492–2498. 2004.
View Article : Google Scholar
|
|
8
|
Herman JG and Baylin SB: Gene silencing in
cancer in association with promoter hypermethylation. N Engl J Med.
349:2042–2054. 2003. View Article : Google Scholar
|
|
9
|
Kuang SQ, Ling X, Sanchez-Gonzalez B, Yang
H, Andreeff M and Garcia-Manero G: Differential tumor suppressor
properties and transforming growth factor-beta responsiveness of
p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA
methylation. Oncogene. 26:1439–1448. 2007. View Article : Google Scholar
|
|
10
|
Takeuchi S, Matsushita M, Zimmermann M,
Ikezoe T, Komatsu N, Seriu T, Schrappe M, Bartram CR and Koeffler
HP: Clinical significance of aberrant DNA methylation in childhood
acute lymphoblastic leukemia. Leuk Res. 35:1345–1349. 2011.
View Article : Google Scholar
|
|
11
|
Hafner C, Schmitz G, Meyer S, Bataille F,
Hau P, Langmann T, Dietmaier W, Landthaler M and Vogt T:
Differential gene expression of Eph receptors and ephrins in benign
human tissues and cancers. Clin Chem. 50:490–499. 2004. View Article : Google Scholar
|
|
12
|
Himanen JP and Nikolov DB: Eph receptors
and ephrins. Int J Biochem Cell Biol. 35:130–134. 2003. View Article : Google Scholar
|
|
13
|
Batlle E, Bacani J, Begthel H, Jonkheer S,
Gregorieff A, van de Born M, Malats N, Sancho E, Boon E, Pawson T,
et al: EphB receptor activity suppresses colorectal cancer
progression. Nature. 435:1126–1130. 2005. View Article : Google Scholar
|
|
14
|
Vaught D, Brantley-Sieders DM and Chen J:
Eph receptors in breast cancer: Roles in tumor promotion and tumor
suppression. Breast Cancer Res. 10:2172008. View Article : Google Scholar
|
|
15
|
Nosho K, Yamamoto H, Takahashi T, Mikami
M, Taniguchi H, Miyamoto N, Adachi Y, Arimura Y, Itoh F, Imai K and
Shinomura Y: Genetic and epigenetic profiling in early colorectal
tumors and prediction of invasive potential in pT1 (early invasive)
colorectal cancers. Carcinogenesis. 28:1364–1370. 2007. View Article : Google Scholar
|
|
16
|
Wang J, Kataoka H, Suzuki M, Sato N,
Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, et
al: Downregulation of EphA7 by hypermethylation in colorectal
cancer. Oncogene. 24:5637–5647. 2005. View Article : Google Scholar
|
|
17
|
Kuang SQ, Bai H, Fang ZH, Lopez G, Yang H,
Tong W, Wang ZZ and Garcia-Manero G: Aberrant DNA methylation and
epigenetic inactivation of Eph receptor tyrosine kinases and ephrin
ligands in acute lymphoblastic leukemia. Blood. 115:2412–2419.
2010. View Article : Google Scholar
|
|
18
|
Jin W, Luo H and Wu J: Effect of reduced
EPHB4 expression in thymic epithelial cells on thymocyte
development and peripheral T cell function. Mol Immunol. 58:1–9.
2014. View Article : Google Scholar
|
|
19
|
Nguyen TM, Arthur A, Hayball JD and
Gronthos S: EphB and Ephrin-B interactions mediate human
mesenchymal stem cell suppression of activated T-cells. Stem Cells
Dev. 22:2751–2764. 2013. View Article : Google Scholar
|
|
20
|
Noyan F, Lieke T, Taubert R, Sievers M,
Dywicki J, Hapke M, Falk CS, Manns MP, Jaeckel E and
Hardtke-Wolenski M: Naive tumour-specific CD4+ T cells were
efficiently primed in acute lymphoblastic leukaemia. Scand J
Immunol. 80:161–168. 2014. View Article : Google Scholar
|
|
21
|
Hegazy AN and Klein C: Ex vivo priming of
CD4 T cells converts immunological tolerance into effective
antitumor immunity in a murine model of acute lymphoblastic
leukemia. Leukemia. 22:2070–2079. 2008. View Article : Google Scholar
|
|
22
|
Takahashi Y, Itoh M, Nara N and Tohda S:
Effect of EPH-ephrin signaling on the growth of human leukemia
cells. Anticancer Res. 34:2913–2918. 2014.
|
|
23
|
Li YH, Wen FQ, Chen YX, Li CG, Zhang ZX,
Chen XW and Li B: Effect of methylation inhibitor on EphB4 gene
expression, proliferation and apoptosis in CEM cells. Zhongguo Dang
Dai Er Ke Za Zhi. 14:205–209. 2012.(In Chinese).
|
|
24
|
Stary J, Zimmermann M, Campbell M,
Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D,
Jazbec J, et al: Intensive chemotherapy for childhood acute
lymphoblastic leukemia: Results of the randomized intercontinental
trial ALL IC-BFM 2002. J Clin Oncol. 32:174–184. 2014. View Article : Google Scholar
|
|
25
|
Mai H, Liu X, Chen Y, Li C, Cao L, Chen X,
Chen S, Liu G and Wen F: Hypermethylation of p15 gene associated
with an inferior poor long-term outcome in childhood acute
lymphoblastic leukemia. J Cancer Res Clin Oncol. 142:497–504. 2016.
View Article : Google Scholar
|
|
26
|
Shen L, Toyota M, Kondo Y, Obata T, Daniel
S, Pierce S, Imai K, Kantarjian HM, Issa JP and Garcia-Manero G:
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle
regulatory pathway with prognostic impact in adult acute
lymphocytic leukemia. Blood. 101:4131–4161. 2003. View Article : Google Scholar
|
|
27
|
Adusumalli S, Omar Mohd MF, Soong R and
Benoukraf T: Methodological aspects of whole-genome bisulfite
sequencing analysis. Brief Bioinform. 16:369–379. 2015. View Article : Google Scholar
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real- time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
29
|
Rutkowski R, Mertens-Walker I, Lisle JE,
Herington AC and Stephenson SA: Evidence for a dual function of
EphB4 as tumor promoter and suppressor regulated by the absence or
presence of the ephrin-B2 ligand. Int J Cancer. 131:E614–E624.
2012. View Article : Google Scholar
|
|
30
|
Pasquale EB: Eph receptors and ephrins in
cancer: Bidirectional signalling and beyond. Nat Rev Cancer.
10:165–180. 2010. View Article : Google Scholar
|
|
31
|
Ferguson BD, Liu R, Rolle CE, Tan YH,
Krasnoperov V, Kanteti R, Tretiakova MS, Cervantes GM, Hasina R,
Hseu RD, et al: The EphB4 receptor tyrosine kinase promotes lung
cancer growth: A potential novel therapeutic target. PLoS One.
8:e676682013. View Article : Google Scholar
|
|
32
|
Fu T, Li P, Wang H, He Y, Luo D, Zhang A,
Tong W, Zhang L, Liu B and Hu C: c-Rel is a transcriptional
repressor of EPHB2 in colorectal cancer. J Pathol. 219:103–113.
2009. View Article : Google Scholar
|
|
33
|
Kumar SR, Scehnet JS, Ley EJ, Singh J,
Krasnoperov V, Liu R, Manchanda PK, Ladner RD, Hawes D, Weaver FA,
et al: Preferential induction of EphB4 over EphB2 and its
implication in colorectal cancer progression. Cancer Res.
69:3736–3745. 2009. View Article : Google Scholar
|
|
34
|
Davalos V, Dopeso H, Castaño J, Wilson AJ,
Vilardell F, Romero-Gimenez J, Espin E, Armengol M, Capella G,
Mariadason JM, et al: EPHB4 and survival of colorectal cancer
patients. Cancer Res. 66:8943–8948. 2006. View Article : Google Scholar
|
|
35
|
Kullander K and Klein R: Mechanisms and
functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol.
3:475–486. 2002. View
Article : Google Scholar
|
|
36
|
Xiao Z, Carrasco R, Kinneer K, Sabol D,
Jallal B, Coats S and Tice DA: EphB4 promotes or suppresses
Ras/MEK/ERK pathway in a context-dependent manner: Implications for
EphB4 as a cancer target. Cancer Biol Ther. 13:630–637. 2012.
View Article : Google Scholar
|
|
37
|
Noren NK, Foos G, Hauser CA and Pasquale
EB: The EphB4 receptor suppresses breast cancer cell tumorigenicity
through an Abl-Crk pathway. Nat Cell Biol. 8:815–825. 2006.
View Article : Google Scholar
|
|
38
|
Almog N, Ma L, Raychowdhury R, Schwager C,
Erber R, Short S, Hlatky L, Vajkoczy P, Huber PE, Folkman J and
Abdollahi A: Transcriptional switch of dormant tumors to
fast-growing angiogenic phenotype. Cancer Res. 69:836–844. 2009.
View Article : Google Scholar
|
|
39
|
Jørgensen C, Sherman A, Chen GI,
Pasculescu A, Poliakov A, Hsiung M, Larsen B, Wilkinson DG, Linding
R and Pawson T: Cell-specific information processing in segregating
populations of Eph receptor ephrin-expressing cells. Science.
326:1502–1509. 2009. View Article : Google Scholar
|
|
40
|
Dopeso H, Mateo-Lozano S, Mazzolini R,
Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi
S, Hernández-Losa J, et al: The receptor tyrosine kinase EPHB4 has
tumor suppressor activities in intestinal tumorigenesis. Cancer
Res. 69:7430–7438. 2009. View Article : Google Scholar
|
